A practical reference on circadian rhythm: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-16. Anything still debated is marked as such rather than presented as settled.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
plasmid Any small DNA molecule that is physically separated from the larger body of chromosomal DNA and can replicate independently. Plasmids are typically small (less than 100 kbp), circular, double-stranded DNA molecules in prokaryotes such as bacteria, though they are also sometimes present in archaea and eukaryotes.
=== 2025: Australian Open final, 500th win === Alongside Team Germany, Zverev failed to defend the United Cup after withdrawing from the event due to injury. Entering the 2025 Australian Open as the second seed for the first time in his career, Zverev began his tournament with a dominant victory over 2019 semifinalist Lucas Pouille in the first round. He reached his second consecutive and third overall semifinal at the Australian Open defeating Pedro Martínez, Jacob Fearnley, Ugo Humbert, and Tommy Paul. Against the 24-time major champion, Zverev won the 81-minute first set against Djokovic before the latter's retirement due to injury, advancing to his third major final. In the final, Zverev lost to defending champion Jannik Sinner in straight sets. Following his defeat to Sinner, a visibly distraught Zverev delivered an emotional speech during the trophy ceremony, stating, "I want to thank my team... I'm just not good enough. It's as simple as that." In the post-match press conference, he reflected on his career trajectory and the pressure of being a perennial contender without a Major title, reportedly remarking that he "didn't want to be the best player in history without a Grand Slam", expressing his desperation to finally break the barrier after losing his third major final. Over the next two months, Zverev made quarterfinals at the South American events he played in, Buenos Aires and Rio de Janeiro, losing to Argentines Francisco Cerundolo and Francisco Comesana, respectively.
Moniz began his experiments with leucotomy just three months after the congress had reinforced the apparent cause-and-effect relationship between the Fulton and Jacobsen presentation and the Portuguese neurologist's resolve to operate on the frontal lobes. As the author of this account, Fulton, who has sometimes been claimed as the father of lobotomy, was later able to record that the technique had its true origination in his laboratory. Endorsing this version of events, in 1949, the Harvard neurologist Stanley Cobb remarked during his presidential address to the American Neurological Association that "seldom in the history of medicine has a laboratory observation been so quickly and dramatically translated into a therapeutic procedure". Fulton's report, penned ten years after the events described, is, however, without corroboration in the historical record and bears little resemblance to an earlier unpublished account he wrote of the congress. In this previous narrative, he mentioned an incidental, private exchange with Moniz, but it is likely that the official version of their public conversation he promulgated is without foundation. In fact, Moniz stated that he had conceived of the operation sometime before his journey to London in 1935, having told in confidence his junior colleague, the young neurosurgeon Pedro Almeida Lima, as early as 1933 of his psychosurgical idea.
=== Phlebitis === Phlebitis is the inflammation of a vein. It is usually accompanied by a blood clot when it is known as thrombophlebitis. When the affected vein is a superficial vein in the leg, it is known as superficial thrombophlebitis, and unlike deep vein thrombosis there is little risk of the clot breaking off as an embolus.
Sources: en.wikipedia.org
== Burkina Faso == Thomas Sankara - Military officer, pan-African revolutionary, President of Burkina Faso. Hama Arba Diallo – Politician, diplomat and civil servant former minister of foreign affairs, former vice-president of the National Assembly, Burkina Faso Salif Diallo – former president of National Assembly; former Minister of Environment and Water, former Minister of Agriculture, Burkina Faso Yéro Boly – Administrator, Diplomat and Politician, former Minister of Territorial Administration and Security, former director of the Cabinet of the president and former minister of defense; Burkina Faso. Amadou Dicko - Minister of animal resources. Chérif Sy – journalist, politician, former president of the National Transitional Council of Burkina Faso, former acting president of Burkina Faso (17 September 2015 – 23 September 2015). Current minister of defense; Burkina Faso Alpha Barry – Journalist, current minister of foreign affairs; Burkina Faso Aminata Diallo Glez – Filmmaker, actress and producer, Burkina Faso Boubacar Diallo (filmmaker) – Journalist, Filmmaker, Burkina Faso Sékou Ba – Politician, former Minister of Animal Resources, Burkina Faso Dicko Fils - Singer
Negative selection (background depletion or subtraction) targets and eliminates the host and microbiome genomic background, while aiming to preserve the nucleic acid derived from the pathogens of interest. Degradation of genomic background can be performed through broad-spectrum digestion with nucleases, such as DNase I for DNA background, or by removing abundant RNA species (rRNA, mtRNA, globin mRNA) using sequence-specific RNA depletion kits. Also CRISPR-Cas9-based approaches can be performed to target and deplete human mitochrondrial RNA for example. Generally, however, subtraction approaches lead to a certain degree of loss of the targeted pathogen genome, as poor recovery may occur during the cleanup. Positive enrichment is used to increase pathogen signal rather than reducing background noise. This is commonly done through hybridization-based target capture by probes, which are used to pull out nucleic acid of interest for downstream amplification and sequencing. Panviral probes have been shown to successfully identify diverse types of pathogens in different clinical fluid and respiratory samples, and have been used for sequencing and characterization of novel viruses. However, the probe approach includes extra hybridization and cleanup steps, requiring higher sample input, increasing the risk of losing the target, and increasing the cost and hands-on time. High-throughput sequencing: all the nucleic acids fragments of the library are sequenced.
An alcohol treated with at least 3 equivalents of an activated halide (such as allyl bromide or iodomethane) and CDI yields the corresponding halide with good yield. Bromination and iodination work best, though this reaction does not preserve the stereochemistry of the alcohol. In a similar context, CDI is often used in dehydration reactions. As CDI is an equivalent of phosgene, it can be used in similar reaction, however, with increased selectivity: it allows the synthesis of asymmetric bis alkyl carbonates
Sources: en.wikipedia.org
Firstly, the NADH + H+ generated by glycolysis has to be transferred to the mitochondrion to be oxidized, and thus to regenerate the NAD+ necessary for glycolysis to continue. However the inner mitochondrial membrane is impermeable to NADH and NAD+. Use is therefore made of two "shuttles" to transport the electrons from NADH across the mitochondrial membrane. They are the malate-aspartate shuttle and the glycerol phosphate shuttle. In the former the electrons from NADH are transferred to cytosolic oxaloacetate to form malate. The malate then traverses the inner mitochondrial membrane into the mitochondrial matrix, where it is reoxidized by NAD+ forming intra-mitochondrial oxaloacetate and NADH. The oxaloacetate is then re-cycled to the cytosol via its conversion to aspartate which is readily transported out of the mitochondrion. In the glycerol phosphate shuttle electrons from cytosolic NADH are transferred to dihydroxyacetone to form glycerol-3-phosphate which readily traverses the outer mitochondrial membrane. Glycerol-3-phosphate is then reoxidized to dihydroxyacetone, donating its electrons to FAD instead of NAD+. This reaction takes place on the inner mitochondrial membrane, allowing FADH2 to donate its electrons directly to coenzyme Q (ubiquinone) which is part of the electron transport chain which ultimately transfers electrons to molecular oxygen O2, with the formation of water, and the release of energy eventually captured in the form of ATP.
Penicillamine, which contains nitrogen and sulphur donor atoms, is used as this type of ligand binds more strongly to copper ions than to calcium and magnesium ions. Treatment of poisoning by heavy metals such as lead and mercury is more problematical, because the ligands used do not have high specificity relative to calcium. For example, EDTA may be administered as a calcium salt to reduce the removal of calcium from bone together with the heavy metal. Factors determining selectivity for lead against zinc, cadmium and calcium have been reviewed.
== Bibliography == Bonagura J., DVM; et al. (2000). Current Veterinary Therapy. Vol. 13. pp. 321–381. Cossar, Harper (2011). Letterboxed: The Evolution of Widescreen Cinema. University Press of Kentucky. ISBN 978-0-813-12651-7. Halliwell, Martin (2013). Therapeutic Revolutions: Medicine, Psychiatry, and American Culture, 1945-1970. Rutgers University Press. ISBN 978-0-813-56066-3. Ingle DJ (October 1950). "The biologic properties of cortisone: a review". J. Clin. Endocrinol. Metab. 10 (10): 1312–54. doi:10.1210/jcem-10-10-1312. PMID 14794756. Woodward R. B.; Sondheimer F.; Taub D. (1951). "The Total Synthesis of Cortisone". Journal of the American Chemical Society. 73 (8): 4057. Bibcode:1951JAChS..73.4057W. doi:10.1021/ja01152a551.
=== Legal status === In Russia bupropion is banned as a narcotic drug, due to it being a derivative of methcathinone. In Australia, France, and the UK, smoking cessation is the only licensed use of bupropion, and no generics are marketed.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.